Market capitalization | $743.91m |
Enterprise Value | $390.10m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.05 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-100.09m |
Free Cash Flow (TTM) Free Cash Flow | $-64.98m |
Cash position | $360.13m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Tyra Bioscience forecast:
7 Analysts have issued a Tyra Bioscience forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.48 -0.48 |
45%
45%
|
|
EBITDA | -100 -100 |
44%
44%
|
EBIT (Operating Income) EBIT | -100 -100 |
44%
44%
|
Net Profit | -84 -84 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
Head office | United States |
CEO | Todd Harris |
Employees | 49 |
Founded | 2018 |
Website | www.tyra.bio |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.